The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis

Low prices and excess supply have pushed oil & gas balance sheets to the brink, which means raising traditional debt will remain difficult and restructurings are expected

Practical advice on restructuring processes and considerations

Remote working, online shopping and telemedicine have shielded the technology sector from the worst effects of COVID-19 lockdowns

The year started strongly for many nations in Latin America, but coronavirus has heavily impacted the M&A market.

COVID-19 has pushed healthcare systems around the world to the limit, but depending on the vertical, certain companies have been less affected than those in other sectors—and the availability of credit to battle the pandemic has helped